Efficacy and safety in tirzepatide‐treated Korean adults with type 2 diabetes—A post hoc analysis of <scp>SURPASS</scp> ‐ <scp>AP</scp> ‐combo and <scp>SURPASS</scp> ‐3
Consistent with the overall results of the SURPASS-AP-Combo and SURPASS-3 trials, this post hoc subgroup analysis found clinically meaningful reductions in HbA1c and body weight after treatment periods of 40 to 52 weeks in Koreans with T2D treated with tirzepatide.
Authors
- Byung‐Wan Lee (ORCID: https://orcid.org/0000-0002-9899-4992)
- Soo Kyung Lim (ORCID: https://orcid.org/0000-0002-4137-1671)
- Min Ju Kang (ORCID: https://orcid.org/0000-0002-7736-6073)
- Nan Hee Kim (ORCID: https://orcid.org/0000-0003-4378-520X)
- Jong Chul Won (ORCID: https://orcid.org/0000-0002-2219-4083)
- Li Du (ORCID: https://orcid.org/0000-0002-3867-337X)
- Chang Beom Lee (ORCID: https://orcid.org/0000-0003-4891-834X)
- Sin Gon Kim (ORCID: https://orcid.org/0000-0002-7430-3675)
- Howard J. Lim (ORCID: https://orcid.org/0000-0002-5814-714X)
- Kyu Jeung Ahn (ORCID: https://orcid.org/0000-0002-4648-3605)
- Woo Je Lee (ORCID: https://orcid.org/0000-0002-1899-3560)
- Ju Young Yuh
Institutions
- Ulsan College (KR)
- Eli Lilly (United States) (US)
- Yonsei University (KR)
- Korea University (KR)
- Asan Medical Center (KR)
- Seoul National University Bundang Hospital (KR)
- Ansan University (KR)
- University of Ulsan (KR)
- Inje University Sanggye Paik Hospital (KR)
- Hanyang University Guri Hospital (KR)
- Kyung Hee University Hospital at Gangdong (KR)
- Korea University (JP)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-09-15
- DOI
- https://doi.org/10.1111/dom.70111
- Primary Topic
- Traditional Chinese Medicine Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company